The Preeclampsia Diagnostics Market size was valued at USD 1.22 Billion in 2023 and is expected to reach USD 1.59 Billion By 2032 with a growing CAGR of 2.98% over the forecast period of 2024-2032.
To Get More Information on Preeclampsia Diagnostics Market - Request Sample Report
The Preeclampsia Diagnostics Market is experiencing robust growth, driven by advancements in diagnostic technologies and increasing awareness of maternal health risks. Preeclampsia, a hypertensive disorder affecting 2%–8% of pregnancies globally, remains a leading cause of maternal and neonatal mortality. The condition’s rising prevalence, attributed to factors such as obesity, advanced maternal age, and pre-existing health conditions like hypertension and diabetes, underscores the urgent need for early and accurate diagnostic solutions.
Recent advancements in diagnostic technologies have significantly enhanced early detection capabilities. For instance, biomarkers such as placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are used in diagnostic assays, demonstrating high sensitivity and specificity in predicting preeclampsia. Non-invasive testing methods, including blood-based and urine-based assays, have gained traction due to their accuracy and convenience. Moreover, a study published in 2023 highlighted the use of artificial intelligence (AI)-driven predictive models, which achieved over 90% accuracy in early detection using maternal health data and biomarkers.
Public health initiatives have further contributed to market growth. For example, the establishment of World Preeclampsia Day has brought global attention to the condition, emphasizing the importance of early screening and intervention. Campaigns led by organizations like the Preeclampsia Foundation aim to educate healthcare providers and expectant mothers on recognizing symptoms and risks, fostering increased adoption of diagnostic tools.
However, challenges persist. Despite an estimated 20+ candidate diagnostics under investigation, the number of approved diagnostic products remains low. Accessibility in low-resource settings also hinders widespread adoption, where the burden of preeclampsia is often highest. Efforts to address these gaps include the development of cost-effective, point-of-care diagnostic solutions, which are expected to improve accessibility and maternal health outcomes.
Drivers
Advances in Precision Medicine for Risk-Based Diagnostics
The growing emphasis on personalized medicine has transformed the landscape of preeclampsia diagnostics. By leveraging genomics and proteomics, healthcare providers can now identify high-risk pregnancies with greater accuracy. These advancements facilitate the early detection and management of preeclampsia, significantly reducing complications for both mothers and infants. Tailored diagnostic solutions ensure that care is optimized based on individual risk profiles, supporting proactive healthcare measures. This personalized approach aligns with the global shift toward precision medicine, making it a pivotal driver in the market's expansion.
Technological Innovations in Diagnostic Solutions
Cutting-edge technologies, such as microfluidic systems and molecular diagnostics, are revolutionizing preeclampsia testing. These innovative methods deliver rapid and accurate results, meeting the critical need for timely diagnosis in point-of-care settings. The portability and cost-effectiveness of these tools make them particularly valuable in remote or resource-limited areas. As healthcare systems adopt these advanced diagnostics, they ensure better clinical outcomes by enabling swift interventions. These technological advancements underscore the industry's commitment to enhancing diagnostic efficacy.
AI and Investment in Maternal Health Infrastructure
Artificial intelligence and machine learning are increasingly integrated into preeclampsia diagnostics, enabling predictive analytics and early warnings for clinicians. These AI-driven platforms analyze complex datasets to identify potential risks with remarkable precision. Concurrently, investments in maternal healthcare infrastructure, supported by government and private sector initiatives, improve access to diagnostic tools globally. Collaborative programs also promote the development of low-cost, point-of-care solutions, ensuring that advanced diagnostics reach underserved populations. Together, these efforts are reshaping maternal healthcare and driving market growth.
Restraints
Limited Accessibility and High Costs in Low-Resource Settings
A significant restraint in the preeclampsia diagnostics market is the limited accessibility and affordability of advanced diagnostic solutions in low-resource regions. While innovative technologies like molecular diagnostics and AI-driven platforms are transforming the market, their high costs and infrastructure requirements pose challenges for widespread adoption, particularly in developing countries. Many healthcare facilities in these areas lack the necessary equipment and trained personnel to implement advanced diagnostics effectively. Additionally, the high out-of-pocket expenses for patients further limit their accessibility. Addressing this disparity requires focused efforts to develop cost-effective, point-of-care solutions and expand healthcare infrastructure in underserved regions to ensure equitable access to life-saving diagnostic tools.
By Test Type
In 2023, blood tests emerged as the dominant segment, contributing over 60% of the market share. This dominance is attributed to their precision in detecting biomarkers like placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1), which are crucial for early and accurate diagnosis of preeclampsia. Blood tests are widely utilized in healthcare facilities due to their high reliability and the availability of standardized testing protocols. Their ability to detect the condition in its early stages ensures timely medical intervention, further cementing their leading position in the market.
Urine analysis is the fastest-growing segment, gaining popularity for its non-invasive nature and ease of administration. With innovations in diagnostic techniques such as proteinuria dipstick tests, urine analysis offers a practical solution for early detection, particularly in resource-limited settings. Its accessibility and patient-friendly approach drive its rapid adoption across healthcare facilities worldwide.
By Product
The consumables segment, including reagents, test strips, and assay kits, accounted for approximately 55% of the market share in 2023. These products are essential for conducting diagnostic tests, resulting in recurring demand from laboratories and healthcare providers. Their affordability and compatibility with various diagnostic platforms make them indispensable for blood and urine testing, reinforcing their market dominance.
Instruments, such as automated analyzers and portable diagnostic devices, represent the fastest-growing product segment. The demand for advanced instruments is rising due to their ability to deliver rapid and precise results. Their increasing adoption in point-of-care and remote healthcare settings reflects the growing need for efficient and reliable diagnostic solutions. These innovations are reshaping the market by expanding access to high-quality diagnostics.
North America led the Preeclampsia Diagnostics Market in 2023, driven by advanced healthcare systems, high maternal health awareness, and access to state-of-the-art diagnostic technologies. In the U.S., significant investments in maternal healthcare and a focus on personalized medicine have led to the widespread adoption of blood tests and innovative diagnostic instruments. Government support, including research funding and initiatives to improve maternal health, further bolsters market growth in this region.
Europe closely followed, with countries like Germany, the UK, and France at the forefront of preeclampsia diagnostics. The region’s commitment to enhancing maternal healthcare and integrating innovative diagnostic technologies into everyday clinical practice drives market expansion. A robust regulatory environment in Europe also facilitates the swift adoption of advanced solutions, including AI-powered diagnostic tools and molecular testing, which continue to gain traction in healthcare facilities across the region.
The Asia-Pacific region is rapidly emerging as a high-growth preeclampsia diagnostics market. With rising awareness of preeclampsia and increasing healthcare access, countries like India and China are seeing a surge in demand for diagnostic solutions. The growing prevalence of high-risk pregnancies, with the adoption of mobile and point-of-care diagnostic technologies, is a key factor driving market growth. Additionally, the region’s improving healthcare infrastructure is making advanced diagnostic solutions more accessible, contributing to the ongoing expansion of the market.
Do You Need any Customization Research on Preeclampsia Diagnostics Market - Enquire Now
Elecsys sFlt-1 Immunoassay
PerkinElmer Inc.
DELFIA Xpress Preeclampsia Test
DRG Preeclampsia Risk Test
B·R·A·H·M·S KRYPTOR Preeclampsia Risk Test
Diabetomics, Inc.
Preeclampsia Risk Panel
Metabolomic Diagnostics Ltd.
Metabolomic Diagnostic Test for Preeclampsia
Sera Prognostics
PreTRM Test
Siemens Healthineers AG
Atellica IM sFlt-1 and PlGF Immunoassays
Bayer AG
Adiana Preeclampsia Test
Bio Rad Laboratories Inc.
BioPlex 2200 System
BioCheck Inc.
sFlt-1 and PlGF ELISA Assay Kit
bioMerieux SA
VIDAS Preeclampsia
Diabetomics Inc.
Preeclampsia Risk Panel
Sysmex Corporation
Sysmex Preeclampsia Test
Fujirebio Diagnostics
Fujirebio Pre-eclampsia Tests
Siemens Healthineers AG
Atellica IM sFlt-1 and PlGF Immunoassays
ACON Laboratories Inc.
ACON Preeclampsia Test
In Dec 2024, Gravidas Diagnostics was awarded USD 3 million by ARPA-H to develop a home-based fingerstick test for preeclampsia. The test aims to detect sFlt‐1 levels in the bloodstream through a colorimetric assay.
In Sept 2024, Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management, acquired Metabolomics Diagnostics, an Irish company focused on biomarker-based diagnostics for complex diseases. The acquisition, valued at approximately USD 1.3 million, involved over 270,000 Trinity Biotech ADS, along with cash and the assumption of liabilities.
In May 2023, CSEM’s Tools for Life Sciences team partnered with the innovative Swiss start-up MOMM Diagnostics to develop a revolutionary point-of-care solution for preeclampsia diagnostics. This advanced multiplexed sensing device was designed to simultaneously detect two key biomarkers associated with the disease.
| Report Attributes | Details |
| Market Size in 2023 | USD 1.22 Billion |
| Market Size by 2032 | USD 1.59 Billion |
| CAGR | CAGR of 2.98% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Test Type (Blood Tests, Urine Analysis) • By Product (Instruments, Consumables) • By End-user (Hospitals, Specialty Clinics, Diagnostic Centers, Others |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | F. Hoffmann-La Roche Ltd, PerkinElmer Inc., DRG Instruments GmbH, Thermo Fisher Scientific Inc., Diabetomics, Inc., Metabolomic Diagnostics Ltd., Sera Prognostics, Siemens Healthineers AG, Bayer AG, Bio Rad Laboratories Inc., BioCheck Inc., bioMerieux SA, Sysmex Corporation, Fujirebio Diagnostics, and ACON Laboratories Inc. |
| Key Drivers | • Advances in Precision Medicine for Risk-Based Diagnostics • Technological Innovations in Diagnostic Solutions • AI and Investment in Maternal Health Infrastructure |
| Restraints | • Limited Accessibility and High Costs in Low-Resource Settings |
The Preeclampsia Diagnostics Market is to grow at 2.98% Over the Forecast Period 2024-2032.
Ans: The Preeclampsia Diagnostics Market size was valued at USD 1.22 Billion in 2023.
Ans: The Preeclampsia Diagnostics Market is to Hit USD 1.59 Billion by 2032.
Ans: Measurements of blood pressure are frequently used as a preeclampsia screening method.
Ans: F. Hoffmann-La Roche Ltd, PerkinElmer Inc., DRG Instruments GmbH, Thermo Fisher Scientific Inc., Diabetomics, Inc., Metabolomic Diagnostics Ltd., Sera Prognostics, Siemens Healthineers AG, Bayer AG, Bio Rad Laboratories Inc., BioCheck Inc., bioMerieux SA, Sysmex Corporation, Fujirebio Diagnostics, and ACON Laboratories Inc.
Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Diagnostic Trends (2023), by Region
5.3 Test Volume, by Region (2020-2032)
5.4 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Preeclampsia Diagnostics Market Segmentation, by Test Type
7.1 Chapter Overview
7.2 Blood Tests
7.2.1 Blood Tests Market Trends Analysis (2020-2032)
7.2.2 Blood Tests Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Urine Analysis
7.3.1 Urine Analysis Market Trends Analysis (2020-2032)
7.3.2 Urine Analysis Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Preeclampsia Diagnostics Market Segmentation, by Product
8.1 Chapter Overview
8.2 Instruments
8.2.1 Instruments Market Trends Analysis (2020-2032)
8.2.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Consumables
8.3.1 Consumables Market Trends Analysis (2020-2032)
8.3.2 Consumables Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Preeclampsia Diagnostics Market Segmentation, by End-user
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2020-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Specialty Clinics
9.3.1 Specialty Clinics Market Trends Analysis (2020-2032)
9.3.2 Specialty Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Diagnostic Centers
9.4.1 Diagnostic Centers Market Trends Analysis (2020-2032)
9.4.2 Diagnostic Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Others
9.5.1 Others Market Trends Analysis (2020-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Preeclampsia Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.2.4 North America Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.5 North America Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.2.6.2 USA Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.6.3 USA Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.2.7.2 Canada Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.7.3 Canada Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.2.8.2 Mexico Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.8.3 Mexico Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.6.3 Poland Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.7.3 Romania Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.1.9 turkey
10.3.1.9.1 Turkey Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.5 Western Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.6.3 Germany Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.7.2 France Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.7.3 France Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.8.2 UK Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.8.3 UK Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.9.3 Italy Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.10.3 Spain Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.13.3 Austria Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Preeclampsia Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.5 Asia Pacific Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.6.2 China Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.6.3 China Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.7.2 India Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.7.3 India Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.8.2 Japan Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.8.3 Japan Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.9.2 South Korea Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.9.3 South Korea Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.10.3 Vietnam Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.11.2 Singapore Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.11.3 Singapore Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.12.2 Australia Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.12.3 Australia Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Preeclampsia Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.1.4 Middle East Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.5 Middle East Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.6.3 UAE Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.2.4 Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.5 Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Preeclampsia Diagnostics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.6.4 Latin America Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.5 Latin America Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.6.6.2 Brazil Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.6.3 Brazil Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.6.7.2 Argentina Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.7.3 Argentina Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.6.8.2 Colombia Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.8.3 Colombia Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Preeclampsia Diagnostics Market Estimates and Forecasts, by Test Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Preeclampsia Diagnostics Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Preeclampsia Diagnostics Market Estimates and Forecasts, by End-user (2020-2032) (USD Billion)
11. Company Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product / Services Offered
11.1.4 SWOT Analysis
11.2 DRG Instruments GmbH
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product / Services Offered
11.2.4 SWOT Analysis
11.3 Thermo Fisher Scientific Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product / Services Offered
11.3.4 SWOT Analysis
11.4 Metabolomic Diagnostics Ltd.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product / Services Offered
11.4.4 SWOT Analysis
11.5 Sera Prognostics
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product / Services Offered
11.5.4 SWOT Analysis
11.6 Siemens Healthineers AG
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product / Services Offered
11.6.4 SWOT Analysis
11.7 Bio Rad Laboratories Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product / Services Offered
11.7.4 SWOT Analysis
11.8 BioCheck Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product / Services Offered
11.8.4 SWOT Analysis
11.9 bioMerieux SA
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product / Services Offered
11.9.4 SWOT Analysis
11.10 Sysmex Corporation
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product / Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Test Type
Blood Tests
Urine Analysis
By Product
Instruments
Consumables
By End-user
Hospitals
Specialty Clinics
Diagnostic Centers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The ATP Assays Market valued USD 0.93 billion in 2023 which is expected to boost USD 1.98 billion by 2032, CAGR 8.77% over the forecast period 2024-2032.
The Personal Mobility Device Market size was valued at USD 12.35 billion in 2023 and is expected to reach USD 23.48 billion by 2032, growing at a CAGR of 7.37% over the forecast period of 2024-2032.
The Cold Pain Therapy Market Size was valued at USD 1.91 billion in 2023, and is expected to reach USD 2.96 billion by 2032, and grow at a CAGR of 5% over the forecast period 2024-2032.
The Angioplasty Balloon Market size was estimated at USD 3.05 billion in 2023 and will hit USD 4.18 billion by 2031 growing at a CAGR of 4.01% by 2024-2031.
The Subcutaneous Drug Delivery Devices Market was worth USD 30.92 billion in 2023 and is predicted to be worth USD 56.95 billion by 2032, growing at a CAGR of 7.07% between 2024 and 2032.
The Arrhythmia Monitoring Devices Market Size was valued at USD 7.18 billion in 2023 and is expected to reach USD 13.08 billion by 2032 and grow at a CAGR of 6.9% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
